Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-20093 injection in advanced esophageal cancer and other advanced solid tumors
CTR20233477Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risvutatug rezetecan in esophageal cancer and Nonhematologic neoplasms, sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Objective response rate. Started Feb 2024; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
esophageal cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20233477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233477.